May 18, 2006
Uniferon® has been approved by the
Veterinary Medicines Directorate in the United Kingdom (UK) and
replaces Leodex®. Uniferon® is Pharmacosmos'
veterinary iron dextran compound for injection and the worldwide
leading injectable iron dextran solution for prevention of iron
deficiency anemia in piglets.
Leodex® in the UK
Since 1992, Pharmacosmos has supplied the active pharmaceutical
ingredient (API) in Leodex® veterinary iron dextran
solution for injection. Leodex® has been marketed by Leo
Laboratories Ltd., a UK subsidiary of Danish-based pharmaceutical
company Leo Pharma A/S. As a natural extension of Pharmacosmos'
commitment the UK customers, Pharmacosmos is pleased to announce
that the company agreed to acquire Leo Laboratories Ltd.'s
marketing authorization of Leodex® earlier in 2006.
Uniferon® replaces Leodex®
As an important part of the procedure of acquiring the marketing
authorization of Leodex®, Pharmacosmos has decided to
let Uniferon® replace Leodex® as product
name. This will allow UK customers to benefit from the strong
awareness of the documented positive effects of
Uniferon®. Today, Uniferon® has been approved
by the UK Veterinary Medicines Directorate.
Injection of Uniferon® provides high 200 mg iron per
ml for treatment and is an efficient method to prevent iron
deficiency anemia. Ensuring healthy and vigorous growth in piglets,
Uniferon® has been approved in all major countries
including the United States (US).
Please read more information
about Uniferon® or visit the Uniferon
About Pharmacosmos A/S
Pharmacosmos develops and markets
medicines for the treatment of iron deficiency. A research-based
company, its ongoing R&D programme focuses on improving the
treatment options for healthcare professionals, patients suffering
from iron deficiency and veterinary treatments. .
Pharmacosmos is a family-owned
Danish company and operates in more than 50 countries across
Europe, the Americas and Asia. Its facilities are approved by both
the Danish Medicines Agency and the US Food & Drug